https://www.aigom.it/wp-content/uploads/2026/05/ART26.5-1.png431400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-26 08:14:012026-05-26 08:15:37PREVALENCE AND REACTIVATION OF HEPATITIS B AND C IN PATIENTS UNDERGOING CHEMOTHERAPY FOR SOLID TUMORS.
https://www.aigom.it/wp-content/uploads/2026/05/Screenshot-2026-05-19-095945-Copia.png480600Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-19 08:01:482026-05-19 08:01:48ERADICATION OF HELICOBACTER PYLORI IN THE PRIMARY PREVENTION OF GASTRIC CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
https://www.aigom.it/wp-content/uploads/2026/05/Screenshot-2026-05-12-122913.png633400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-12 10:31:232026-05-12 10:31:23RISK OF BREAST CANCER AFTER OVARIAN CANCER IN WOMEN WITH A PATHOGENIC/LIKELY PATHOGENIC VARIANT IN BRCA1 OR BRCA2.
https://www.aigom.it/wp-content/uploads/2026/05/Screenshot-2026-05-05-104358.png400311Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-05 08:28:522026-05-05 08:49:21PEMBROLIZUMAB OR PLACEBO WITH CHEMORADIOTHERAPY FOLLOWED BY PEMBROLIZUMAB OR PLACEBO FOR NEWLY DIAGNOSED, HIGH-RISK, LOCALLY ADVANCED CERVICAL CANCER (ENGOT-cx11/GOT-3047/KEYNOTE-A18): A RANDOMISED, DOUBLE-BLIND, PHASE 3 CLINICAL TRIAL.
